Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
1301 | 8126 | 31.5 | 76% |
Classes in level above (level 3) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
385 | 29018 | ANTIPHOSPHOLIPID SYNDROME//SYSTEMIC LUPUS ERYTHEMATOSUS//ANTIPHOSPHOLIPID ANTIBODIES |
Classes in level below (level 1) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | ANTIPHOSPHOLIPID SYNDROME | Author keyword | 1274 | 63% | 16% | 1293 |
2 | ANTIPHOSPHOLIPID ANTIBODIES | Author keyword | 1159 | 68% | 13% | 1019 |
3 | LUPUS ANTICOAGULANT | Author keyword | 864 | 72% | 8% | 672 |
4 | ANTICARDIOLIPIN ANTIBODIES | Author keyword | 726 | 71% | 7% | 585 |
5 | BETA2 GLYCOPROTEIN I | Author keyword | 628 | 83% | 4% | 358 |
6 | ANTI BETA2 GLYCOPROTEIN I ANTIBODIES | Author keyword | 185 | 94% | 1% | 65 |
7 | ANTICARDIOLIPIN ANTIBODY | Author keyword | 178 | 66% | 2% | 166 |
8 | CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME | Author keyword | 177 | 83% | 1% | 99 |
9 | ANTIPHOSPHOLIPID ANTIBODY | Author keyword | 140 | 60% | 2% | 152 |
10 | ANTICARDIOLIPIN | Author keyword | 127 | 65% | 2% | 122 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ANTICARDIOLIPIN ANTIBODIES | 1929 | 61% | 25% | 2066 |
2 | BETA2 GLYCOPROTEIN I | 1451 | 78% | 12% | 958 |
3 | ANTI BETA2 GLYCOPROTEIN I ANTIBODIES | 500 | 89% | 3% | 231 |
4 | RECOGNIZE BETA2 GLYCOPROTEIN I | 397 | 94% | 2% | 141 |
5 | BETA 2 GLYCOPROTEIN I APOLIPOPROTEIN H | 382 | 94% | 2% | 133 |
6 | ANTIPHOSPHOLIPID ANTIBODIES | 380 | 35% | 11% | 896 |
7 | INTERNATIONAL CONSENSUS STATEMENT | 321 | 61% | 4% | 345 |
8 | ANTICOAGULANT | 315 | 32% | 10% | 821 |
9 | ANTI CARDIOLIPIN ANTIBODIES | 310 | 84% | 2% | 167 |
10 | LUPUS ANTICOAGULANT | 296 | 52% | 5% | 408 |
Journals |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | LUPUS | 77 | 14% | 6% | 496 |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | 2006 | 1875 | 123 | 85% |
Medical progress: The antiphospholipid syndrome. | 2002 | 772 | 78 | 92% |
The Pathogenesis of the Antiphospholipid Syndrome | 2013 | 94 | 99 | 71% |
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study | 2015 | 3 | 14 | 93% |
Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies | 2015 | 3 | 23 | 87% |
Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment | 2015 | 3 | 144 | 72% |
Diagnosis and management of non-criteria obstetric antiphospholipid syndrome | 2015 | 2 | 58 | 84% |
Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: Analysis of 24 cases from the bibliography review | 2015 | 2 | 23 | 78% |
Pathogenesis of antiphospholipid syndrome: understanding the antibodies | 2011 | 95 | 77 | 79% |
Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome | 2014 | 16 | 66 | 89% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ANTIPHOSPHOLIPID STANDARDIZAT | 65 | 95% | 0.3% | 21 |
2 | LUPUS UNIT | 60 | 38% | 1.5% | 124 |
3 | AUTOIMMUNE DIS | 35 | 20% | 2.0% | 159 |
4 | BARBARA VOLCKER WOMEN RHEUMAT DIS | 34 | 69% | 0.4% | 29 |
5 | ALLERGY CLIN IMMUNOL RHEUMATOL UNIT | 21 | 64% | 0.3% | 21 |
6 | SERV MALALTIES AUTOIMMUNES | 15 | 42% | 0.3% | 28 |
7 | CELL CHEM | 15 | 30% | 0.5% | 42 |
8 | CLIN MED DERMATOL | 12 | 34% | 0.4% | 29 |
9 | HLA VASC BIOL | 9 | 52% | 0.1% | 12 |
10 | RIC IMMUNOL CLIN IMMUNOPATOL DOCUMENTAZ M | 9 | 67% | 0.1% | 8 |
Related classes at same level (level 2) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000034055 | SYSTEMIC LUPUS ERYTHEMATOSUS//LUPUS//LUPUS NEPHRITIS |
2 | 0.0000011546 | CONGENITAL HEART BLOCK//NEONATAL LUPUS//NEONATAL LUPUS ERYTHEMATOSUS |
3 | 0.0000009818 | PURPURA FULMINANS//SYMMETRICAL PERIPHERAL GANGRENE//CARCINOCYTHEMIA |
4 | 0.0000008890 | HYPEREMESIS GRAVIDARUM//MOTHERISK PROGRAM//NAUSEA AND VOMITING OF PREGNANCY |
5 | 0.0000008219 | PROTEIN C//ACTIVATED PROTEIN C//TISSUE FACTOR |
6 | 0.0000007604 | CHOLESTEROL CRYSTAL EMBOLIZATION//CHOLESTEROL EMBOLI//CHOLESTEROL CRYSTAL EMBOLISM |
7 | 0.0000006994 | HEPARIN INDUCED THROMBOCYTOPENIA//ARGATROBAN//LEPIRUDIN |
8 | 0.0000006187 | WEGENERS GRANULOMATOSIS//GIANT CELL ARTERITIS//VASCULITIS |
9 | 0.0000005900 | PRE ECLAMPSIA//HYPERTENSION IN PREGNANCY//HELLP SYNDROME |
10 | 0.0000005868 | THROMBOTIC THROMBOCYTOPENIC PURPURA//ADAMTS 13//HEMOLYTIC UREMIC SYNDROME |